REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-19. Numbers and descriptions here follow the published literature rather than marketing material.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, dark | Protect from repeated temperature changes. |
| Common analytical method | LC-MS or HPLC-UV | Reference standard required for comparison. |
| Common synonyms | SR9009; Stenabolic; REV-ERB agonist | Vendor naming may vary. |
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Further contributions of Gil-Av and associates are concerned with the use of chiral mobile phase additives (CMPAs) in liquid chromatography (LC), enantiomeric separation of helicenes by supramolecular LC, the temperature-dependent reversal of enantioselectivity by enthalpy-entropy compensation and non-linear effects leading to enantiomeric enrichment during chromatography on achiral stationary phases.
TV1 and TV2 were postulated during an early analysis of human and murine genes in 2002. Both transcription variants share the first 399 amino acids, but differ at the following 16 amino acids for TV1 and ten amino acids for TV2, respectively. This is linked to the exon usage. While they share the first eight exons, TV1 is using exon 10and TV2 exon 9 to finish their respective sequence. The third transcription variant was postulated after a data bank analysis in the year 2014. The proposed sequence is sharing the first 399 amino acids with TV1 and TV2, but differs in the upcoming 28 amino acids. The exon usage of TV3 consists of exon 1 to 8, which is followed by exon 11 to finish the sequence. Besides various sequences of the three different transcription variants, the variants also show differences in Michaelis-Menten kinetic parameters (Km and Vmax) in regard to their potential to phosphorylate canonical (α-casein) as well as non-canonical (GST-β-catenin1-181) substrates (Xu et al., 2019). TV3 shows an increase of phosphorylation of both substrates compared to TV1 and TV2, which is statistically significant. These differences can be explained by various degrees of autophosphorylation of the transcription variants.
=== Breast changes === Spironolactone can cause breast pain and enlargement in women. This is "probably because of estrogenic effects on target tissue." At low doses, breast tenderness has been reported in only 5% of women, but at high doses, it has been reported in up to 40% of women. Breast enlargement and tenderness may occur in 26% of women at high doses. Some women regard spironolactone-induced breast enlargement as a positive effect. Spironolactone also commonly and dose-dependently produces gynecomastia (breast development) as a side effect in men. At low doses, the rate is only 5 to 10%, but at high doses, up to or exceeding 50% of men may develop gynecomastia. In the RALES, 9.1% of men taking 25 mg/day spironolactone developed gynecomastia, compared to 1.3% of controls. Conversely, in studies of healthy men given high-dose spironolactone, gynecomastia occurred in 3 of 10 (30%) at 100 mg/day, in 5 of 8 (62.5%) at 200 mg/day, and in 6 of 9 (66.7%) at 400 mg/day, relative to none of 12 controls. The severity of gynecomastia with spironolactone varies considerably, but is usually mild. As with breast enlargement caused by spironolactone in women, gynecomastia due to spironolactone in men is often, although inconsistently, accompanied by breast tenderness. In the RALES, only 1.7% of men developed breast pain, relative to 0.1% of controls. The time to onset of spironolactone-induced gynecomastia has been found to be 27 ± 20 months at low doses and 9 ± 12 months at high doses.
=== 11 May === The Ukrainian army said that they had broken through advancing Russian formations northwest of Bakhmut. Geolocated footage showed Ukrainian troops counterattacking near Khromove and Bila Hora, which Russian forces were trying to seize in order to encircle the city. Ukrainian sources said their forces advanced 2.6 km (1.6 mi) along a 3 km-wide (1.9-mile) front, destroying the 6th and 8th companies of the Russian 72nd Separate Motor Rifle Brigade; the head of the Wagner Group, Yevgeny Prigozhin, said already on 9 May that Russian troops had abandoned some positions on his flank in Bakhmut. The claim was also shared by Russian military bloggers but denied by the Russian Defence Ministry, which said that Russian forces repelled a surge of Ukrainian attacks in Soledar and that its forces had fallen back to "more favourable positions" near the Berkhivka reservoir northwest of Bakhmut for tactical reasons. The United Kingdom Secretary for Defence Ben Wallace announced that the UK supplied Ukraine with Storm Shadow missiles. With a range of 250 kilometres, the missiles are capable of hitting targets in Crimea from the positions currently held by Ukraine. The United States supported the UK's decision.
Sources: en.wikipedia.org
== Further reading == Stogner JM (December 2014). "The potential threat of acetyl fentanyl: legal issues, contaminated heroin, and acetyl fentanyl "disguised" as other opioids". Annals of Emergency Medicine. 64 (6): 637–9. doi:10.1016/j.annemergmed.2014.07.017. PMID 25153008.
A recent systematic review and meta-analysis compared the results of published animal studies and identified that improved outcomes are reported with the use of hybrid (mixed) scaffolds and cell seeding; however, the meta-analysis of these results were not in agreement with the evaluation of descriptive results from the review. Therefore, further studies involving larger animals and novel scaffolds, and more transparent reproduction of previous studies are advisable.
==== Drones ==== Drones are roughly comparable in intelligence and social status to that of the Culture's biological members. Their intelligence is measured against that of an average biological member of the Culture; a so-called "1.0 value" drone would be considered the mental equal of a biological citizen, whereas lesser drones such as the menial service units of Orbitals are merely proto-sentient (capable of limited reaction to unprogrammed events, but possessing no consciousness, and thus not considered citizens; these take care of much of the menial work in the Culture). The sentience of advanced drones has various levels of redundancy, from systems similar to that of Minds (though much reduced in capability) down to electronic, to mechanical and finally biochemical back-up brains. Although drones are artificial, the parameters that prescribe their minds are not rigidly constrained, and sentient drones are full individuals, with their own personalities, opinions and quirks. Like biological citizens, Culture drones generally have lengthy names. They also have a form of sexual intercourse for pleasure, called being "in thrall", though this is an intellect-only interfacing with another sympathetic drone.
== Career == Huttenlocher joined the faculty at the University of Wisconsin–Madison (UW-M) in 1999 with a joint appointment in the Departments of Pediatrics and Pharmacology, and as an associate director of the Medical Scientist Training Program (MSTP). In this role, Huttenlocher's research has defined cellular and molecular mechanisms that regulate cell migration and identified basic adhesive mechanisms that regulate cell migration and leukocyte chemotaxis. By 2005, her research team had identified a novel pathway that turned out to be critical for cell migration and chemotaxis, involving intracellular proteolysis by the calcium-dependent protease calpain. Her laboratory was also the first to document reverse migration of neutrophils away from sites of injury or inflammation. In 2011 her group reported the first redox sensor that mediates leukocyte attraction to wounds. In 2005 she was elected a member of the American Society for Clinical Investigation. Huttenlocher was promoted to Professor with tenure in 2008 and was the recipient of the Graduate School’s H.I. Romnes Fellowship award. She also received the Burroughs-Wellcome Fund’s Clinical Scientist Award in Translational Research for her project "Diagnosis and Treatment of Autoinflammatory Disease." Huttenlocher was the recipient of a 2011 WARF Kellett Mid-Career Award. Until 2023 she conducted this work while maintaining an active clinical practice as a pediatric rheumatologist. In 2012, Huttenlocher was appointed as Director of the UW-Madison MD-PhD training program (MSTP), succeeding Deane Mosher.
Freight containers are a reusable transport and storage unit for moving products and raw materials between locations or countries. There are about seventeen million intermodal containers in the world, and a large proportion of the world's long-distance freight generated by international trade is transported in shipping containers. In addition, it is estimated that several million of these containers have now been discarded due to the shipping cost of sending them back to their port of origin. Their invention made a major contribution to the globalization of commerce in the second half of the 20th century, dramatically reducing the cost of transporting goods and hence of long-distance trade. Specialized shipping containers include: high cube containers (providing an extra 1 ft (305 mm) in height to standard shipping containers), pallet wides, open tops, side loaders, double door or tunnel-tainers, and temperature controlled containers. Another specialized container, known as Transtainer, is a portable fuel and oil freight container. The hybrid bulk fuel tank is originally intended for the construction, mining, logging and farming sectors. The tank can be used to transport and store bulk fuels as well as dangerous liquids, by road, rail and sea. Sea containers are crucial for modern logistics, offering a cost-effective storage and shipping solution. These durable containers, designed for international transportation, provide secure storage for goods with robust steel construction. Beyond shipping, they find applications in on-site storage and modular living or workspaces.
Sources: en.wikipedia.org
The Hok/sok system a post-segregational killing system of the plasmid, toxin-antitoxin system hok: encodes a toxin that kills cells without the plasmid. sok: short anti-sense RNA that inhibits hok mRNA translation in plasmid carrying cells.
=== Systemic lupus erythematosus === The role of Th22 cells in systematic lupus erythematous (SLE) is still unclear. In some patients levels of Th22 cells and interleukin-22 (IL-22) were increased, which correlated with disease activity, but decreased levels of interleukin-22 (IL-22) and Th22 cells were also reported. Interleukin-22 (IL-22) is a cytokine involved in recruiting neutrophils in response to microbe invading, and in the case of lupus, it seems that interleukin 22 (IL-22) is involved in inflammatory and pathological processes via recruiting of immune cells. On the other hand, Th22 cells might be a better predictor of systematic lupus erythematous (SLE) development than Th17 cells.
=== Enhancement of physical performance === 1-MNA acts as a myokine, supporting the utilization of amino acids for gluconeogenesis in the liver and stimulating lipolysis in adipose tissue, thereby providing energy for muscles. Studies indicate that 1-MNA supplementation improves exercise tolerance and reduces fatigue. After one month of supplementation with 58 mg of 1-MNA, post-COVID-19 patients reported improved distances in a 6-minute walk test (6MWT), with 92% of participants experiencing better outcomes compared to controls. Additional studies highlight 1-MNA's ability to enhance physical performance by stimulating PGI2 release, protecting microcirculation, and ensuring adequate blood flow to muscle tissues. This mechanism may reduce cardiovascular risks associated with physical exertion, particularly in individuals with impaired endothelial response.
== History == TAP tagging was invented by a research team working in the European Molecular Biology Laboratory in the late 1990s (Rigaut et al., 1999, Puig et al., 2001) and proposed as a new tool for proteome exploration. It was used by the team to characterize several protein complexes (Rigaut et al., 1999, Caspary et al. 1999, Bouveret et al., 2000, Puig et al., 2001). The first large-scale application of this technique was in 2002, in which the research team worked in collaboration with scientists of the proteomics company Cellzome to develop a visual map of the interaction of more than 230 multi-protein complexes in a yeast cell by systematically tagging the TAP tag to each protein. The first successful report of using TAP tag technology in plants came in 2004 (Rohila et al., 2004,)
Hydrophobicity scales are values that define the relative hydrophobicity or hydrophilicity of amino acid residues. The more positive the value, the more hydrophobic are the amino acids located in that region of the protein. These scales are commonly used to predict the transmembrane alpha-helices of membrane proteins. When consecutively measuring amino acids of a protein, changes in value indicate attraction of specific protein regions towards the hydrophobic region inside lipid bilayer. The hydrophobic or hydrophilic character of a compound or amino acid is its hydropathic character, hydropathicity, or hydropathy.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.
The solid is usually kept desiccated at -20 °C or lower and protected from light. Stock solutions are aliquoted to limit freeze–thaw cycles. Aqueous solutions are not generally recommended for long-term storage.
Laws differ by country and by intended use. It is not an approved medicine, and many vendors sell it as a research chemical. Purchasers are responsible for confirming local restrictions.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.